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Abstract
Background Skeletal muscle mass and function are partly maintained by the supply of amino acids, altered amino acid
transport is an important cause of frailty that can lead to decreased independence with increasing age and slow trauma
recovery. The system-A sodium coupled neutral amino acid transporter (SNAT)-2 coded by gene family SLC38A2
generates a 506 amino acid 56 kDa protein that is an important transporter of amino acids in skeletal muscle. Ageing
is associated with a decrease in expression of SNAT2 transporters.
Methods In this study, we used the C2C12 cell line, using myoblast cells and cells differentiated into myotubes. We
investigated if the expression of SNAT2 DNA would enhance intracellular amino acid levels and increase their
availability for protein synthesis.
Results In control myoblasts and myotubes, we found significantly decreased expression of SNAT2 (6.5× decrease,
n= 4 per group, P < 0.05) in myotubes than found in myoblasts. After transfection with a SNAT2-eGFP cDNA plasmid,
C2C12 myoblasts significantly increased perinuclear punctate SNAT2-eGFP expression that persisted and was more cy-
toplasmic after differentiation into myotubes. Interestingly, transfected cells were significantly more responsive to the
hormone 5α-dihydrotestosterone (DHT, 4.5 nM, by 1.6×, n= 3 per group, P < 0.04). Starvation significantly enhanced
the amino acid C14-MeAIB transport (1.7×, n = 3 per group, P < 0.05) indicating increased function of SNAT2.
Inhibiting SNAT2 with high concentrations of MeAIB (3.3 or 5 mM) significantly reduced C14-Isoleucine transport by
L-type amino acid transporter (LAT2, 52.8% and 77%, respectively, n = 3 per group, P < 0.05). However, there was
no increase in the LAT2 transport of C14-isoleucine detectable in SNAT2-eGFP transfected cells after DHT (4.5 nM)
exposure. This indicated that small amino acid availability was not rate limiting to LAT2 function in myoblasts.
Conclusions Overall, these data show that transfection of SNAT2-eGFP expression enhanced its function following
starvation and treatment with physiological levels of DHT. Enhanced SNAT2 expression in muscle cells offers a viable
epigenetic target in pathological conditions associated with altered amino acid transport.
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Introduction
Skeletal muscle is a major site of metabolic activity and is the
most abundant tissue in the human body.1 Studies of humans
indicate that by the age of 70, there is a ~25–30% reduction
in the cross-sectional area of skeletal muscle and a decline
in muscle strength by ~30–40%.2 They have further shown a
decrease in protein synthesis with ageing; however, the
anabolic effect of amino acids is intact in elderly muscle3
and argues an imbalance between protein synthesis and
breakdown that implies that altered amino acid transport
into skeletal muscle may be a contributing factor.
Age-related muscle atrophy and weakness is characterized
both by the loss of lean muscle mass and reduced skeletal
muscle strength and is a major contributor to frailty and loss
of independence in older people.4,5 Muscle maintenance and
homeostasis has a complex aetiology and the primary
biochemical and molecular mechanisms underlying the
processes have not been fully identified. Possible causes that
have been linked to compromised muscle homeostasis are
aberrant ROS production,6 changes in amino-acid transport,7
loss of motor units,8,9 altered hormone levels,10 changes in
satellite cell number,11 changes in physical activity,12 and
chronic inflammation.13 What is clear is that fast twitch (Type
II) glycolytic muscle fibres are more susceptible to ageing as-
sociated muscle deficits than slow twitch (Type I) oxidative
muscle fibres.14
Transport of amino acids into skeletal muscle is achieved
through transporters on the sarcolemma, the two most
usually found expressed in skeletal muscle being the
sodium-coupled neutral amino acid transporter (SNAT)-2
and the sodium independent L-type amino acid transporter
(LAT)-2.15 Importantly, these two transporters can work to-
gether to transport different amino acid types into muscle
cells or fibres. SNAT2 transports small neutral amino acids
such as glutamine, glycine, and alanine with one sodium ion
into muscle fibres that can then be exchanged by the
anti-porter LAT216 for larger (more difficult to transport)
branched chain amino acids, such as isoleucine, valine, and
leucine, that are essential for protein synthesis. The LAT2
substrate leucine has been found to be anabolic17 compared
to valine and isoleucine. Reports indicate decreased expres-
sion of SNAT2 protein in old as compared to younger skeletal
muscle, an observation more pronounced in fast twitch than
slow twitch skeletal muscle.18 There was no change in mRNA
for SNAT2 (or LAT2), although increased peEF2 (eukaryotic
elongation factor-2) was found in fast twitch muscle fibres
that may explain the tissue heterogeneity.18 Therefore, one
hypothesis that may contribute to pathological conditions in
muscle involving perturbed amino acid transport is that re-
duced SNAT2 expression could limit the availability of small
amino acids, for protein synthesis, thereafter also leading to
reduced transport by LAT2 of branched chain amino acids es-
sential for protein synthesis. SNAT2 expression has been
shown to be increased in response to a DHT treatment,18 in-
creasing from internal sources and not by transcription.19
Taken together, these observations make SNAT2 a possible
target for intervention to maintain amino acid transport to
mitigate conditions that could compromise muscle protein
homeostasis.
We used the C2C12 cell line as it is a myogenic precursor
cell that can be differentiated into mature myotubes.20,21
We expressed a GFP tagged SNAT2 cDNA, transfected it into
myoblasts and investigated uptake by SNAT2 and LAT2 of
amino acid substrates (i.e. C14-α-(methylamino)isobutyric
acid (MeAIB) and C14-isoleucine, respectively) to determine
effects on transporter function and sensitivity to physiologi-




The cell line C2C12 (CRL-1772) is an immortal line of mouse
skeletal myoblasts originally derived from the satellite cells
of a C3H mouse donor after an injury of the animal’s thigh.22
Cells were used up to passage 3 and grown in DMEM
(Invitogen UK) with 10% fetal bovine serum (FBS, Sigma-
Aldrich, Dorsett, UK), 2 mM L-glutamine (Sigma-Aldrich) and
1% penicillin/streptomycin (Invitrogen, UK). Cells were split
at ~70% confluence, and myogenic differentiation was
induced in DMEM with 2% horse serum supplemented with
2 mM L-glutamine and 1% penicillin/streptomycin to initiate
terminally differentiated myotubes23 for a minimum of 5 days
with daily media changes.
Drug treatments
5α-Dihydrotestosterone (DHT; Sigma-Aldrich, Dorset,
England) was dissolved in ethanol at 4.5 nM, and equivalent
vehicle was added to controls and filtered using a 0.2 μm
filter, 1 h prior to the start of an experiment. An antagonist
was used, Flutamide at 3 μM (Tocris, Abingdon, England).
Cells were starved in HBSS (Sigma-Aldrich) for a total of
150 min. Where indicated, amino acid supplement of 1.1%
amino acids were added and FBS increased to 20% for
150 min to act as overfed.
Cloning SNAT2-eGFP
The gene sequence NM_175121 for SNAT2 (see Supporting
Information, Figure S1A) was cloned into the vector
pcDNA3.1-C-eGFP by Genscript (Leiden, Netherlands),
hereafter identified as SNAT2-eGFP. Thereafter, 10 ng of
2 T. Pearson et al.
Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12707
plasmid was heat shocked into E. coli strain DH5α (Invitrogen,
Thermo Fisher, UK) in a small amount of SOC media. The
transformed E. coli were grown in antibiotic free LB-broth
for 6 h and then a small amount spread on agar plates
containing 100 mg/mL ampicillin (Sigma-Aldrich) and grown
overnight at 37°C. A selection of colonies were picked the
next day and grown in separate flasks of LB-broth
containing 100 mg/mL ampicillin for 16 h on a shaking
incubator at 37°C at 800 rpm. Thereafter, the LB was
centrifuged in universal tubes to pellet the E. coli, the
plasmid DNA was extracted from the cells using standard
methods (Plasmid mini-prep, Macherey Nagel, Fisher
Scientific, Leicestershire, England). The final plasmid DNA
was checked for quality by a spectrophotometer and a
small amount run on a 2% agarose gel (Sigma-Aldrich) after
cutting at selected restriction sites (using standard
methods), see Supporting Information, Figure S1B.
Transfection
Myoblast cells were grown on glass cover slips coated with
laminin (50 μg/cm2). In brief, 0.5 μg per well of plasmid
SNAT2-eGFP DNA was transfected by Lipofectamine 2000
(Thermo Fisher) into cells by standard techniques. Briefly,
cells were grown on coverslips till approximately 70–80%
confluent and then transfected with Lipofectamine for 24 h
and then washed with media. The coverslips were then used
as indicated for additional experiments. Other transfections
were carried out in an identical manner using 6-well plates
or T25 flasks. Transfection efficiency was determined from
four separate transfections, where at least three coverslips
per transfection were counted for the number of GFP positive
cells. This analysis indicated 16 ± 1.3% (range 13–19.3%) GFP
positive cells. Transfections that failed to attain this approxi-
mate efficiency range of transfection were not used. Control
cells were transfected identically using vehicle alone.
Immunocytochemistry
Cells were fixed with 4% PFA and permeabilized by exposure
to 2% NP40/2% methanol, primary antibody for SNAT2
(SNAT2 H-60 Sc-166,366 mouse monoclonal, Santa
Cruz, USA) was used at 1:50 in 1% BSA/TBST, secondary anti-
bodies were applied in 2% BSA/TBST for 1 h at room temper-
ature by standard procedures and stained with DAPI. Control
coverslips had no primary antibody.
Cells were imaged on a Zeiss Imager M2 Apotome
microscope with a 63×, 1.4 NA oil-immersion objective, and
images were captured using AxioVision V.4.9.1.0 (Carl Zeiss
Microscopy, Germany).
Western blotting
Briefly, cells lysed in RIPA buffer (150 mM sodium chloride,
1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris, pH 8.0) containing 10 mg/10 mL protease inhibitors
(Roche, Switzerland) and 100 μL/10 mL phosphatase inhib-
itors (Calbiochem, Nottingham) generated protein lysates
(in standard 2× Laemmli buffer), which were separated by
standard gel SDS-PAGE electrophoresis and transferred
onto nitrocellulose membranes (BioRad, UK). In some cases,
membranes were cut at certain target kDa weights to allow
different portions of a membrane to be exposed to a
different single primary antibody (see Supporting Informa-
tion, Figure S2). Membranes were blocked for non-specific
antibody binding for 2 h using either 5% milk or 3% BSA
in TBST (Tween 0.037%) and immunoblotted for the
expression of SNAT2 (Sc-166366; Santa Cruz Biotechnology,
USA), GFP (Abcam, Cambridge, UK), GAPDH (Abcam), and
actin (Sigma), whilst HRP conjugated secondary antibodies
were used to visualize protein using SuperSignal WestPico
chemiluminescence substrate (Perbio Science UK Ltd,
Cramlington and Northumberland, UK). Densitometry analy-
sis of a protein of interest was normalized to that samples
actin/GAPDH, and a minimum of three different replicates
were undertaken.
Determining SNAT2 and LAT2 transport in C2C12
cells
C2C12 cell uptake of 68.3 μM C14-α-methylaminoisobutyric
acid (0.8 μCi/mL; C14-MeAIB) or 2 mM C14-isoleucine
(3.46 μCi/mL; C14-Iso, PerkinElmer, Bucks, England) was used
to quantify SNAT2 and LAT2 transport, respectively.
Radio-isotopes were added at the start of each 1 h
experiment.
After 1 h, cells were washed and put into 5 mL glass tubes,
centrifuged at 800 g. The pellet was re-suspended in 100 μL
of lysis buffer and put on ice for 20 min, sonicated with a nee-
dle sonicator until the pellet was dispersed and then centri-
fuged at 13 000 g for 10 min. The pellet was discarded, and
the amino acids in total cell lysate supernatant were counted
by scintillation counting.
Radioactivity in each lysate was determined using a liquid
scintillation counter (Tri-Carb 2250 CA, Canberra-Packard)
by standard procedures. Each experiment was run a mini-
mum of three times, using different cell culture preparations
for each replicate.
Statistical analysis
Data were analysed to determine normality using the Sha-
piro–Wilk test; the P value in all cases indicated that the data
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sets had normal distributions. Data are presented as
mean ± SEM for each experiment. Statistical analysis for
potential differences between groups was determined using
analysis of variance (ANOVA) followed by the post hoc LSD
test. Single comparisons between two experimental condi-
tions were determined by unpaired Student’s t-test. Data
were analysed using SPSS V.22, and P values <0.05 were
considered statistically significant.
Results
SNAT2 expression in C2C12 myoblasts and
myotubes
SNAT2 expression was investigated in low passage myoblast
(Figure 1B, top left) cells or in cells differentiated into
myotubes for 5 days (Figure 1B, top right). Typical results
show strong perinuclear puncta of SNAT2 staining in all
myoblasts (shown in red, Figure 1A indicated by arrows),
whereas myotubes showed more diffuse cytoplasmic fluo-
rescence. Western blotting for the expression of SNAT2
demonstrated a significant difference between myoblast
and myotube SNAT2 expression (Figure 1B; see Supporting
Information, Figure S2, top), the proliferating myoblast cell
expression of SNAT2 was approximately 6.5× more abundant
than that found in terminally differentiated myotube cells
(see Figure 1C, n = 3 per group, Student’s t-test). Myoblasts
are proliferating cells responsible for repairing damaged
myotubes or after merging can generate new myotubes;
therefore, subsequent experiments were undertaken using
myoblasts only.
Effect of starvation or excess amino acid
supplementation upon the de novo expression of
SNAT2 in C2C12 myoblasts
To investigate factors that control SNAT2 expression in C2C12
myoblasts, cells were cultured with additional amino acids
(Fed++) or in HBSS media with no amino acids to induce star-
vation. After 150 min, treated cells were harvested, and pro-
teins were analysed by western blotting (Figure 2A; see
Supporting Information, Figure S2, bottom). There was no
significant effect upon SNAT2 expression in the Fed++ group
when additional excess amino acids were applied, whereas
there was a significant increase in SNAT2 expression follow-
ing starvation (Figure 2B). This indicated that SNAT2 recruit-
ment was induced in a low amino acid environment.
Myoblast cells were then grown in standard media
(Figure 2C) or in HBSS to induce starvation, and after 90 min
starvation, the cells were exposed to differing concentrations
Figure 1 (A) Immunocytochemistry of de novo SNAT2 expression in
C2C12 myoblast and myotube cells. C2C12 myoblast cells (i) were grown
on cover slips for several days; thereafter, cells were probed using an an-
tibody for SNAT2 expression (red), and DAPI (blue) was applied to show
the cells nuclei. Additional cover slips of myoblast cells were differenti-
ated into myotubes (ii) for 5 days and again probed for SNAT2 and DAPI.
Panel (A-i) indicates numerous perinuclear puncta indicating SNAT2 ex-
pression in myoblasts, and several examples of puncta are indicated by
white arrows. Panel (A-ii) shows SNAT2 expression in myotubes indicat-
ing cytoplasmic expression and little evidence of puncta. Scale 20 μm.
(B) Example SNAT2 western blot of myoblast and terminally differenti-
ated myotube cells. Example bright field pictures (top) of cells (scale
bar 20 μm) are shown above the western blot that shows four separate
repeats (middle) from the indicated myoblast and myotube cells (sepa-
rated by a dotted line for clarity) when probed for SNAT2 expression.
The bottom panel shows house keeper protein expression for actin that
was used to validate loading between the sample groups. A secondary
antibody control step was undertaken where the SNAT2 primary anti-
body was not used although it was still exposed to the HRP-conjugated
secondary antibody and shows secondary antibody specificity (where
the dashed line indicates the membrane being cut and no primary anti-
body was applied). The primary antibody for the house keeper actin
was exposed to all parts of the blot. (C) Histogram of densitometry anal-
ysis from the western blot (B) showing a significant reduction in SNAT2
expression (indicated by an asterisk) in myotubes (dark grey) versus myo-
blasts (light grey, n = 4 per group, Student’s t-test, P < 0.05, data pre-
sented as mean ± SEM).
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of C14-MeAIB for one additional hour (total 150 min treat-
ment) to generate a dose–response curve. Figure 2C indi-
cated that starved cells transported more C14-MeAIB from
the media to inside the cell than control fed myoblasts. The
EC50 for fed versus starved was 32 and 26 μm C
14-MeAIB re-
spectively showing greater amino acid uptake by SNAT2 in a
starved environment.
Expression of SNAT2-eGFP in myoblasts
SNAT2 cDNA was synthesized commercially, and the se-
quence is given in the Supporting Information, Figure S1A.
It was cloned into pcDNA3.1-eGFP and characterized by re-
striction digest (see Supporting Information, Figure S1B).
The SNAT2-eGFP DNA was transfected into myoblasts, and
Figure 2 (A) Western blot of myoblast cells probed for expression of
SNAT2 (top) and loading control GAPDH (bottom), three separate repeats
per treatment group of; control, fed++ (given increased amino acid/FBS
supplement) and starved (HBSS) were undertaken, where treatments
were applied for 150 min, and thereafter, western blot sample prepara-
tion was immediately performed. Dotted lines show different groups
for clarity, whilst the dashed line shows where the blot was cut to exclude
primary antibody application to determine secondary antibody specific-
ity. (B) Densitometry analysis of each treatment group in the western blot
(A) showed a significant increase in SNAT2 expression in only the starved
group versus either control or fed++, where b > a, P < 0.05 (n = 3 per
group, one-way ANOVA, data presented as mean ± SEM). (C) Dose–
response curve plot showing fed myoblast control cells (solid square)
and 150 min starved myoblast (open circle) C2C12 cells C14-MeAIB
transport versus increasing C14-MeAIB concentrations, results indicate
enhanced transport at all given concentrations in response to starvation.
Curves fitted using a Boltzmann plot (Origin, Origin Lab Cooperation,
USA).
Figure 3 (A) Fluorescent images of transfected C2C12 myoblast cells. Im-
munocytochemistry shows SNAT2 (i, red indicated combined de novo and
transfected SNAT2), nuclei staining (ii, blue, DAPI), plasmid transfected
SNAT2 (iii, green, SNAT2-eGFP), and a merged image (iv) showing
co-localisation of de novo SNAT2 and SNAT2-eGFP overexpression. Typi-
cal transfection rate of cells was approximately 16%. Scale 100 μm. (B)
Western blot of myoblast cells probed using a polyclonal antibody for
GFP (top) and actin (bottom) used as a loading control, showing control
(untransfected) and SNAT2-eGFP transfected cell protein expression of
GFP at approximately 83 kDa (i.e. SNAT2 + GFP fusion protein weight
combined), n = 3 separate repeats per group separated by a dotted line
for clarity. (C) Densitometry analysis of the western blot (B) showing a
significant difference in the transfected group expression of GFP associ-
ated SNAT2 24 h after SNAT2-eGFP plasmid transfection (Student’s t-test,
n = 3, P < 0.05, data presented as mean ± SEM).
Epigenetic expression of SNAT2 enhances amino acid transport 5
Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12707
the cells were either immunostained for SNAT2 or imaged by
direct fluorescence. The immunostaining corresponded to
the direct GFP fluorescence indicating that the signal was
specific for SNAT2 (Figure 3A, iii), and SNAT2 expression
was confirmed by western blotting using a polyclonal
antibody to the GFP tag (see Figure 3B; see Supporting Infor-
mation, Figure S2) and showed a band for the fusion protein
at approximately 83 kDa. Densitometry analysis showed
significant expression of GFP compared with untransfected
control cells.
SNAT2-eGFP expression (Figure 4A, i) was punctate and
peri-nuclear with some cytoplasmic fluorescence, whereas
endogenous SNAT2 (Figure 4A, ii) was predominantly cyto-
plasmic with some punctate fluorescence. Untransfected cells
shown in Figure 4A(v) showed low levels of endogenous
SNAT2 expression throughout the cytoplasm. Myoblasts
were successfully differentiated for 5 days into myotubes
(Figure 4B), and these myotubes showed some peri-nuclear
and predominantly cytoplasmic punctate fluorescence indi-
cated by white and red arrows, respectively. Overexpressed
SNAT2-eGFP was also diffusely observed throughout the
myotube cytoplasm.
SNAT2 and SNAT2-eGFP functional transport of the
isotope C14-MeAIB
Amino acid transport was measured in cells expressing
SNAT2-eGFP using an amino acid analogue C14-MeAIB, a
substrate for SNAT2 transport. C14-MeAIB transport (in full
media) in control and SNAT2 cDNA transfected C2C12 cells
showed a small but non-significant increase (16.2 ± 9%,
Figure 5A) in C14-MeAIB transport (Student’s t-test, n = 3,
P = 0.3). In control cells, transport of C14-MeAIB was
measured (Figure 5B) in response to DHT (4.5 nM) or
flutamide (3 μM) alone or flutamide followed by DHT
Figure 4 (A) Fluorescent images of SNAT2-eGFP transfected myoblast cells showing, (i) SNAT2-eGFP transfected (white arrows indicate perinuclear
puncta of SNAT2-eGFP, whilst SNAT2-eGFP also extended to other cellular regions without puncta), (ii) immunocytochemistry from de novo SNAT2
(includes SNAT2-eGFP protein), (iii) nuclei stained using DAPI, (iv) merged image (i–iv, white arrows indicate perinuclear puncta of SNAT2-eGFP and
co-localisation of de novo SNAT2 and SNAT2-eGFP). Image (v) shows an increased exposure fluorescent image using image (ii) to show transfected cells
overexpressing SNAT2 and de novo SNAT2 expression from nearby untransfected cells (an untransfected example is indicated by the white arrow) both
being targeted by a primary antibody to SNAT2. Scale 20 μm. (B) Fluorescent image, of two examples, of myoblast cells previously transfected with the
plasmid for SNAT2-eGFP and thereafter differentiated into myotubes (pictured) for 5 days showing retention of SNAT2-eGFP. White arrows indicate
SNAT2 puncta in close proximity to the nuclei with additional SNAT2 puncta being more cytoplasmic and distant (red arrows). Further cytoplasmic
fluorescence of SNAT2-eGFP extended along the length of the myotubes. Scale 25 μm.
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treatment to investigate the androgen receptor hormone
response of endogenous SNAT2 function, because DHT
has been previously shown in primary tissue to significantly
increase amino acid transport by SNAT2.18 Our results show
a significant increase in C14-MeAIB transport after treat-
ment with DHT alone (46 ± 10%, n = 4, one-way ANOVA).
This was entirely blocked by pre-treatment with flutamide,
an androgen receptor antagonist, irrespective of whether
it was followed by DHT, and this confirmed de novo
SNAT2 sensitivity to the hormone DHT via the androgen
receptor.
The effect of DHT exposure (Figure 5C) in C2C12 cells
transfected with the SNAT2-eGFP cDNA plasmid was
investigated. There was an increase in C14-MeAIB transport
in both untransfected and transfected cells following DHT
treatment. The enhancement in the DHT response after
transfection was (207.7 ± 26.6%) significant compared with
DHT treatment of control cells (119.8 ± 5%, n = 3, inset
histogram) and clearly demonstrated physiological sensitivity
of SNAT2-eGFP protein to the hormone DHT.
When cells were starved (Figure 5D) of amino acids with
HBSS for 150 min, there was a significant increase in the
transport of C14-MeAIB in both control and transfected cells
that was again enhanced by SNAT2-eGFP transfection (inset
histogram) although that enhancement was not different
from control.
Figure 5 (A) Myoblast cells were exposed to C14-MeAIB for 1 h, and thereafter, uptake of the C14-MeAIB was measured using scintillation counting;
cells were either not transfected control (light grey) or transfected with SNAT2-eGFP (dark grey). A small but not significant increase in C14-MeAIB
transport was recorded in the transfected myoblasts (Student’s t-test, n = 3 both groups, data presented as mean ± SEM). (B) The effect of the hor-
mone DHT was investigated upon untransfected myoblast cells that were treated as control, DHT (4.5 nM) or pre-treated with the androgen receptor
antagonist flutamide (3 μM) alone or for 1 h prior to an identical DHT exposure. DHT treatment alone resulted in a significant (*) 46 ± 10% increase in
C14-MeAIB transport. Flutamide treatment irrespective of DHT exposure was not different from control (n = 4, one-way ANOVA, P < 0.05, data pre-
sented as mean ± SEM). (C) Myoblast cells were either untreated or exposed to 4.5 nM DHT for 1 h and thereafter exposed to C
14
-MeAIB for one ad-
ditional hour, and the uptake of C14-MeAIB was measured. This was carried out to control (not transfected) and SNAT2-eGFP transfected groups. DHT
significantly increased C14-MeAIB transport in untransfected and transfected myoblasts (n = 3, one-way ANOVA where a > b, P < 0.05). Inset histo-
gram shows the percentage change in the DHT stimulated transport of C
14
-MeAIB calculated from the main figure. Transfected myoblasts showed a
significant enhancement of C14-MeAIB transport (207.7 ± 26.6%, dark grey) versus control untransfected cells (119.8 ± 5%, light grey, n = 3, P < 0.03,
Student’s t-test, data presented as mean ± SEM). (D) Myoblast cells were either fed or starved for 150 min and then exposed to C14-MeAIB for 1 h and
uptake of C14-MeAIB measured in control (not transfected) and SNAT2-eGFP transfected groups. Starvation significantly increased C14-MeAIB transport
in untransfected and transfected myoblasts (n = 3, one-way ANOVA, P< 0.05) versus their not starved controls. Inset histogram reports the percentage
change in starvation induced transport of C
14
-MeAIB shown in the main figure, and no significant increase in C14-MeAIB transport after transfection
(111.6 ± 61.3%, dark grey) was found versus control untransfected cells (52.2 ± 27%, light grey, n = 3, Student’s t-test, P > 0.05, data presented as
mean ± SEM).
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Does SNAT2-eGFP transfection have any effect on
LAT2 transport of C14-isoleucine?
SNAT2-eGFP expression may affect the ability of LAT2 to
transport C14-Iso depending on the intracellular availability
of small amino acids. Figure 6A demonstrated that when
SNAT2 transport of amino acids was blocked by higher doses
of MeAIB, there was a significant dose dependant decline in
C14-Iso transport in control C2C12 cells. This was likely due
to reduced intracellular small amino acid availability for the
LAT2 anti-porter and importantly confirmed a mechanistic
link between SNAT2 transport and LAT2 function. C2C12 cells
either control or transfected with SNAT2-eGFP showed no
difference in C14-Iso transport by LAT2 in full media (Figure
6B), indicating no shortage of small amino acid anti-porter
substrates to facilitate larger amino acid transport by LAT2.
Control and C2C12 cells transfected with SNAT2-eGFP (Figure
6C) had a similar significant (one-way ANOVA) increase in
DHT stimulated C14-Iso transport, that was not different be-
tween control versus transfected cells.
Discussion
In this study, we used the C2C12 cell line to express the SNAT2
amino acid transporter and investigated its function in small
neutral amino acid transport.24 Previous studies have re-
ported from primary tissue a decline in SNAT2 expression with
ageing; for example, in both slow and particularly fast twitch
skeletal muscle fibre types, the authors argue that a decline
in SNAT2 (and LAT2) was a contributor to the pathology of
sarcopenia.18 They further reported a reversal of transporter
loss after DHT treatment. We have built upon this observation
using the C2C12 cell line to examine if SNAT2 overexpression
would yield functional amino acid transporters that were re-
sponsive to physiological stimuli. Importantly we then investi-
gated whether there was a secondary positive effect upon
LAT2 anti-porter transport function to determine a mechanis-
tic link between SNAT2 and LAT2. We chose to investigate
SNAT2 from the SLC38 gene family as it is the only amino acid
transporter (with LAT2) consistently found in skeletal
muscle,15 and importantly, SNAT2 has the ability to transport
a non-metabolizable substrate; methyl-aminoisobutyrate
(MeAIB) used in this study and by others25 to follow SNAT2
transporter function.
SNAT2 expression in myoblasts and myotubes
The overexpression of SNAT2 in myoblasts was maintained
through to mature myotubes (Figure 4B) after differentiation.
This has the potential for its use as an epigenetic intervention
in differentiated cells. Skeletal muscle has a robust innate
Figure 6 Impact of SNAT2 transport function upon LAT2 transport of
C
14
-isoleucine. (A) Histogram showing untransfectedmyoblast cells, where
treatments were control or cells treated with 3.3 mM or 5 mMMeAIB (not
C14) respectively to block SNAT2. Blocking SNAT2 with high dose MeAIB
reduced C
14
-isoleucine transport by LAT2 (52.8 ± 5% and 77 ± 2.5%, respec-
tively), significantly so at both concentrations used (n = 3 per group, one-
way ANOVA, P< 0.05, data presented as mean ± SEM). (B) Myoblast cells
were exposed to C14-Iso for 1 h, and thereafter, uptake of the C14-Iso was
measured, and cells were either not transfected control (light grey) or
transfected with SNAT2-eGFP (dark grey). A small but not significant
(Student’s t-test, P > 0.05) decrease in C14-Iso transport was recorded in
the transfected myoblasts (n = 3 both groups, data presented as
mean ± SEM). (C) Histogram showing C14-isoleucine transport in control
(not transfected) and SNAT2-eGFP transfected C2C12 cells that were ei-
ther untreated or treated with 4.5 nM DHT for 1 h. Treatment with DHT
significantly increased C14-isoleucine transport to a similar level irrespec-
tive of transfection with SNAT2-eGFP (n = 3, one-way ANOVA, P < 0.05,
data presented as mean ± SEM).
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ability to repair after injury through the presence of satellite
cells, whilst muscle fibres are post mitotic having no capacity
to divide or initiate any regeneration.26 We utilized myoblasts
as this cell type is crucial to muscle repair or formation of
new muscle fibres and is relevant as other studies have used
C2C12 cells as a myoblast therapy for systemic delivery of
recombinant proteins.27 Here, the C21C12 cells could be
utilized in a similar way to deliver SNAT2 amino acid trans-
porters to compromised muscle types to potentially aid
recovery from trauma or slow sarcopenia through SNAT2 de-
pendent amino acid transport. The cellular distribution of
SNAT2 after differentiation into myotubes changed from
being predominantly perinuclear in myoblasts to being
more diffuse and cytoplasmic, with less puncta evident in
perinuclear areas in the myotubes. This implied a different in-
ternal distribution of SNAT2-eGFP in myotubes compared
with myoblasts. Endogenous SNAT2 expression in mature
myotubes was 6× lower than detected in myoblasts (Figure
1B,C). Logically, the expression difference of endogenous
SNAT2 demonstrates demand for amino acids of growing pro-
liferating myoblast cells, whereas terminally differentiated
myotubes express less amino acid transporters for cell main-
tenance purposes only as proliferation had ceased. This might
argue a more abundant diffuse distribution of SNAT2 along a
fibre length could contribute to viability.
Effects of stimuli upon SNAT2
SNAT2 expression is reported to be adaptive, and amino acid
removal has been reported to increase SNAT2 protein stabil-
ity and SNAT2 gene transcription.28 Bed rest has been re-
ported to decrease amino acid transporter expression in
older people,29 and the ability of transporters to function
has also been reported to be responsive to amino acid con-
centration levels.30 It was argued that an acute phase over
minutes could recruit SNAT2 from internal pools19 in re-
sponse to amino acid deprivation. This supports our observa-
tion of increased de novo SNAT2 expression in response to a
period of starvation (Figure 2A,B) and that SNAT2-eGFP could
also be recruited in a similar way to contribute to transporter
function in response to stimulus treatments of, for example,
DHT (Figure 5C,D). Importantly, other works observed in-
creased Vmax (maximal transport) rather than Km31–33 argu-
ing an up-regulation in transport by SNAT2 could be solely
accounted for by the quantity of functioning transporters
on the plasma membrane. The mechanism behind the adap-
tive response of SNAT2 availability is unknown although the
time course is reminiscent of insulin upon GLUT4 recruitment
from internal vesicular pools.34
Furthermore, as SNAT2 is a system A transporter, it is re-
ported to be sensitive to trans-inhibition, where accumula-
tion of its substrate causes inhibition of the transporter35
and thus can function to control the intracellular amino acid
cytoplasmic concentration.16 Figure 2C supported this obser-
vation as untransfected fed myoblasts transported less
C14-MeAIB at each concentration investigated as compared
to starved myoblasts, indicating trans-inhibition and a move
of SNAT2 to internal storage sites when exposed to sufficient
amino acid substrates. An observation further supported by
Figure 2A,B, as no change in SNAT2 expression upon being
fed extra amino acids was seen and argued full growth media
was sufficient to saturate the amino acid sensing mechanism
of SNAT2. The mechanism of SNAT2 sensing amino acid levels
is not clearly understood, it has been shown that amino
acid starvation induced up-regulation of SNAT2 is reduced
by PI3K and JNK inhibitors.33 Furthermore, transfection of
SNAT2-eGFP only modestly raised the transport of C14-MeAIB
(16%, Figure 5A) when compared with untransfected cells,
and this important observation indicated that SNAT2-eGFP
was functional in regard of sensing intracellular amino acid
levels as increased transporter expression did not automati-
cally correlate to increased transport; additional stimuli were
required, such as DHT, to activate SNAT2-eGFP transport of
C14-MeAIB.
Are transfected SNAT2 functional?
In this study, it is likely that transfection of SNAT2-eGFP in
only 16 ± 1.3% of cells, generated transporters that were lo-
calized to internal storage sites.19 The significantly greater
transport of C14-MeAIB in response to a DHT treatment after
SNAT2-eGFP transfection than found in control myoblasts in
response to an identical DHT (see Figure 5C, and inset) stim-
ulus argues that the SNAT2-eGFP was functional and able to
be recruited, an observation also supported by the trend of
increased C14-MeAIB transport in response to starvation
(Figure 5D) although that response was more variable. In vivo
it is recommended that ageing humans eat a high quality pro-
tein source shortly after resistance exercise, as a stimulus, to
maximize any anabolic response36 to offset ageing anabolic
blunting. Hawkins et al.37 reported increased DHT production
in men over 40 years of age after exercise.
Is LAT2 function affected by SNAT2 transport of
amino acids?
We investigated whether SNAT2 expression might have a
positive effect upon transport of branched chain amino acids
by LAT2. This could potentially contribute to conditions
where amino acid transport may be compromised, for exam-
ple, sustained bed rest and sarcopenia. We reported that in-
creasing concentrations of the SNAT2 blocker MeAIB (3.3 and
5 mM) significantly reduced the transport by LAT2 of isoleu-
cine and confirmed the crucial importance of SNAT2
transported substrates upon the function of LAT2 transport,
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confirming studies by Hatanaka et al.38 SNAT2 transport of
small amino acids may be an important target to maintain
LAT2 function during muscle stress such as ageing. However,
we reported no significant impact upon LAT2 transport
following SNAT2 transfection (Figure 6B) or a difference in
response to DHT treatment (Figure 6C), indicating that the
availability of small amino acids in this case was not limiting
LAT2 transport. This argues that increasing intracellular
LAT2 anti-porter substrate levels by increasing SNAT2 trans-
porter availability is not a feasible method to increase LAT2
activity directly under normal conditions. Additional work is
needed to accurately define the impact of SNAT2 transport
upon LAT2 function in muscle undergoing a period of pathol-
ogy or stress. It is known the nutrient signal in aged muscle is
not sensed or transduced as well as in young muscle given an
identical nutrient stimulus, such as sensing a flooding dose
of leucine36 which resulted in a lower protein synthesis
response from aged muscle.
Conclusions
These data show that expression of endogenous SNAT2 pro-
tein changes as myoblasts differentiate into myotubes.
SNAT2 expression increased in response to starvation whilst
transport by SNAT2 was also increased after a DHT treat-
ment. Additionally, transport of C14-MeAIB by SNAT2-eGFP
and its responsiveness to DHT and starvation was greater
than that of endogenous SNAT2. Together, these results indi-
cate that if SNAT2 lost during pathology can be restored and
functional, it would be able to increase amino acid concentra-
tions. However, overexpressed SNAT2 had no impact on LAT2
transport of isoleucine under basal conditions, indicating that
intracellular concentrations of small amino acids were not a
limiting factor. The increase in C14-Iso transport to a DHT
treatment was similar, irrespective of transfection, and indi-
cated that LAT2 was responsive to DHT although was not lim-
ited by anti-porter substrate availability provided by SNAT2.
Overall, these data show that SNAT2 may be a target for
epigenetic modification to offset altered amino acid transport
during pathological situations or to enhance amino acid
transport after other stimuli such as exercise.12
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Figure S1: (A) Full nucleotide sequence coding amino acid
transporter SNAT2 (Slc38a2, NM_175121) that yields a 506
amino acid protein (56 kDa, NP_780330). (B) Example restric-
tion digest of pcDNA3.1-C-SNAT2eGFP (SNAT2-eGFP) plasmid
showing, ladder, uncut, single cut using XBal, double cut using
HindIII and NotI restriction enzymes. Uncut plasmid runs to
approximately 4,400 bases, single digest using Xbal linearises
the plasmid with a product of 7,650 bases whilst a double cut
generates two fragments of approximately 1,515 bases, being
SNAT2, and the remainder 6,143 bases being the empty clon-
ing vector.
Figure S2: Blot Figure 1B: Shown are the Western blots from
main text Figure 1B. The membrane was cut into two pieces
to allow separate primary antibody application to each blot
piece. SNAT2 primary antibody was applied to the top blot
portion except to the final 2°Ctrl lane (indicated by dashed
line) to determine any non specific secondary antibody bind-
ing. Primary antibody to actin was applied to the bottom
blot across the whole membrane to act as a loading control
and to validate protein had been loaded in that 2°Ctrl lane i.
e. lane not exposed to SNAT2 primary antibody (above).
Dotted lines indicate different sample groups for clarity. Blot
Figure 2A: Shown are the Western blots from main text
Figure 2A. The membrane was cut into two pieces to allow
separate primary antibody application to each blot piece.
SNAT2 primary antibody was applied to the top blot portion
whilst a primary antibody to GAPDH was applied to the bot-
tom blot except to the final 2°Ctrl lane (indicated by dashed
line) to allow non specific secondary antibody binding to be
determined. Dotted lines indicate different sample groups
for clarity.
Figure S2. Blot Figure 3B: Shown are the Western blots from
main text Figure 3B. The entire membrane was exposed to a
GFP polyclonal primary antibody (top blot) except the final
2°Ctrl lane (indicated by dashed line) which was cut away
and thus allowed non specific secondary antibody binding
to be determined. Primary antibody to actin (bottom blot)
was thereafter applied to all of the membrane and validated
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protein had been loaded in the 2°Ctrl lane not exposed to the
GFP primary antibody (above) and also acted as a loading
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